Alprazolam
Brand names: Xanax (US)
Alprazolam is a short-acting benzodiazepine used for the short-term management of anxiety; it is not routinely recommended in UK practice.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It enhances the inhibitory action of GABA at the GABA-A receptor, increasing chloride channel opening and producing anxiolytic, sedative and muscle-relaxant effects.
Prescribing in practice
- Tolerance and dependence develop readily, so prescribe only for short periods and withdraw gradually to avoid a withdrawal syndrome including seizures.
- Combining with opioids or other CNS depressants markedly increases the risk of sedation and fatal respiratory depression.
- Avoid in patients with a history of substance misuse and use cautiously in the elderly and in hepatic impairment.
Monitoring
Monitor for excessive sedation, signs of dependence and the continuing indication, rather than by laboratory testing.
Counselling the patient
- Do not stop suddenly; the dose must be reduced gradually under medical supervision.
- Avoid alcohol and do not drive if you feel drowsy.
- This medicine is intended for short-term use only.
Evidence & guidelines
MHRA and national guidance advise that benzodiazepines such as alprazolam be used only short-term at the lowest effective dose because of dependence.
Reference: NICE CG113 (GAD); MHRA Drug Safety Update Apr 2020 (benzodiazepines + opioids); Ashton Manual on benzodiazepine withdrawal; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Benzodiazepine Conversion Calculator · Drug Conversion
- Cervical Cerclage Criteria (Short Cervix / Preterm Risk) · Preterm Labour
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- Brief Pain Inventory — Short Form (BPI-SF) · Pain
- CIWA-Ar — Alcohol Withdrawal Scale · Diagnosis
- Montreal Cognitive — Short Screening for Substance Misuse · Substance Misuse Screening
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185